JP2007513976A - Ｈｌａ−ｄｒ特異的抗体、組成物、および方法 - Google Patents

Ｈｌａ−ｄｒ特異的抗体、組成物、および方法 Download PDF

Info

Publication number
JP2007513976A
JP2007513976A JP2006544134A JP2006544134A JP2007513976A JP 2007513976 A JP2007513976 A JP 2007513976A JP 2006544134 A JP2006544134 A JP 2006544134A JP 2006544134 A JP2006544134 A JP 2006544134A JP 2007513976 A JP2007513976 A JP 2007513976A
Authority
JP
Japan
Prior art keywords
hla
seq
antibody
human
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006544134A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007513976A5 (cg-RX-API-DMAC7.html
Inventor
キャサリン ジェイ． マクマハン，
ララ ポーター ステパン，
ライナー ラウス，
ダミール ヴィドヴィック，
Original Assignee
デンドレオン コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by デンドレオン コーポレイション filed Critical デンドレオン コーポレイション
Publication of JP2007513976A publication Critical patent/JP2007513976A/ja
Publication of JP2007513976A5 publication Critical patent/JP2007513976A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2006544134A 2003-12-15 2004-12-15 Ｈｌａ−ｄｒ特異的抗体、組成物、および方法 Pending JP2007513976A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60894403P 2003-12-15 2003-12-15
PCT/US2004/042312 WO2005058251A2 (en) 2003-12-15 2004-12-15 Hla-dr-specific antibodies, compositions and methods

Publications (2)

Publication Number Publication Date
JP2007513976A true JP2007513976A (ja) 2007-05-31
JP2007513976A5 JP2007513976A5 (cg-RX-API-DMAC7.html) 2007-12-27

Family

ID=34700255

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006544134A Pending JP2007513976A (ja) 2003-12-15 2004-12-15 Ｈｌａ−ｄｒ特異的抗体、組成物、および方法

Country Status (5)

Country Link
US (1) US8354507B2 (cg-RX-API-DMAC7.html)
EP (1) EP1711527A4 (cg-RX-API-DMAC7.html)
JP (1) JP2007513976A (cg-RX-API-DMAC7.html)
CA (1) CA2550155C (cg-RX-API-DMAC7.html)
WO (1) WO2005058251A2 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020501512A (ja) * 2016-09-23 2020-01-23 ユニバーシティ オブ サザン カリフォルニア キメラ抗原受容体およびその組成物ならびにそれらの使用の方法
US11667715B2 (en) 2019-02-15 2023-06-06 University Of Southern California Lym-1 and Lym-2 antibody compositions and improved car constructs

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007042809A2 (en) * 2005-10-11 2007-04-19 Domantis Limited Antibody polypeptide library screening and selected antibody polypeptides
GB0525214D0 (en) * 2005-12-12 2006-01-18 Bioinvent Int Ab Biological materials and uses thereof
US9085614B2 (en) * 2008-08-01 2015-07-21 Immunas Pharma, Inc. Antibodies that specifically bind to Aβ oligomers and uses thereof
CA3220104A1 (en) * 2010-06-08 2011-12-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
CN104203982B (zh) 2011-10-28 2018-08-31 特瓦制药澳大利亚私人有限公司 多肽构建体及其用途
JP2016530244A (ja) * 2013-12-31 2016-09-29 ディベロップメント センター フォー バイオテクノロジーＤｅｖｅｌｏｐｍｅｎｔ Ｃｅｎｔｅｒ Ｆｏｒ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ 抗ｖｅｇｆ抗体及びその使用
CA2987992A1 (en) * 2015-06-04 2016-12-08 University Of Southern California Lym-1 and lym-2 targeted car cell immunotherapy
KR20180087430A (ko) * 2015-12-17 2018-08-01 얀센 바이오테크 인코포레이티드 Hla-dr에 특이적으로 결합하는 항체 및 이의 용도
EP3515491A4 (en) 2016-09-21 2020-09-16 Aptevo Research and Development LLC CD123 BINDING PROTEINS AND RELATED COMPOSITIONS AND PROCESSES
JP7280238B2 (ja) * 2017-07-17 2023-05-23 ヤンセン バイオテツク，インコーポレーテツド フィブロネクチンｉｉｉ型ドメインに対する抗原結合領域及びその使用方法
CN113950483B (zh) * 2019-04-01 2025-08-05 中外制药株式会社 抗hla-dq2.5抗体
CN115028730B (zh) * 2022-05-17 2022-11-08 诺赛联合(北京)生物医学科技有限公司 一种成体干细胞衍生的类器官制备方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6336796A (ja) * 1986-08-01 1988-02-17 Teijin Ltd マウス−ヒトキメラ抗体、それをコ−ドする発現型キメラｄｎａ配列、プラスミド及び細胞
WO2000012560A1 (en) * 1998-08-28 2000-03-09 Dendreon Corporation Selective apoptosis of neoplastic cells by an hla-dr specific monoclonal antibody
JP2000517289A (ja) * 1996-01-23 2000-12-26 ジェネンテック インコーポレーテッド 発作に関する抗―ｃｄ１８抗体
JP2002501085A (ja) * 1998-01-23 2002-01-15 エフ．ホフマン−ラ ロシュ アーゲー ヒトｉｌ−１２に対する抗体
JP2002540764A (ja) * 1999-02-12 2002-12-03 ジェネティックス・インスチチュート・インコーポレーテッド Ｂ７分子と反応するヒト化免疫グロブリンおよびそれを用いた治療方法
WO2003033538A1 (en) * 2001-10-15 2003-04-24 Kirin Beer Kabushiki Kaisha Anti-hla-dr antibody
WO2003048321A2 (en) * 2001-12-03 2003-06-12 Alexion Pharmaceuticals, Inc. Hybrid antibodies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO873164L (no) 1986-07-30 1988-02-01 Teijin Ltd Muse-humane kimaere antistoffer.
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
ATE365749T1 (de) 2000-05-12 2007-07-15 Gpc Biotech Ag Humane peptide/proteine, die das töten von zellen,einschliesslich lymphoide tumorzellen, herbeiführen oder bewirken
US8450348B2 (en) * 2007-02-21 2013-05-28 Forma Tm, Llc Derivatives of squaric acid with anti-proliferative activity

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6336796A (ja) * 1986-08-01 1988-02-17 Teijin Ltd マウス−ヒトキメラ抗体、それをコ−ドする発現型キメラｄｎａ配列、プラスミド及び細胞
JP2000517289A (ja) * 1996-01-23 2000-12-26 ジェネンテック インコーポレーテッド 発作に関する抗―ｃｄ１８抗体
JP2002501085A (ja) * 1998-01-23 2002-01-15 エフ．ホフマン−ラ ロシュ アーゲー ヒトｉｌ−１２に対する抗体
WO2000012560A1 (en) * 1998-08-28 2000-03-09 Dendreon Corporation Selective apoptosis of neoplastic cells by an hla-dr specific monoclonal antibody
JP2002540764A (ja) * 1999-02-12 2002-12-03 ジェネティックス・インスチチュート・インコーポレーテッド Ｂ７分子と反応するヒト化免疫グロブリンおよびそれを用いた治療方法
WO2003033538A1 (en) * 2001-10-15 2003-04-24 Kirin Beer Kabushiki Kaisha Anti-hla-dr antibody
WO2003048321A2 (en) * 2001-12-03 2003-06-12 Alexion Pharmaceuticals, Inc. Hybrid antibodies

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020501512A (ja) * 2016-09-23 2020-01-23 ユニバーシティ オブ サザン カリフォルニア キメラ抗原受容体およびその組成物ならびにそれらの使用の方法
US11667715B2 (en) 2019-02-15 2023-06-06 University Of Southern California Lym-1 and Lym-2 antibody compositions and improved car constructs

Also Published As

Publication number Publication date
WO2005058251A3 (en) 2005-11-17
US20050208048A1 (en) 2005-09-22
CA2550155C (en) 2015-03-17
WO2005058251A2 (en) 2005-06-30
CA2550155A1 (en) 2005-06-30
EP1711527A4 (en) 2008-09-03
EP1711527A2 (en) 2006-10-18
US8354507B2 (en) 2013-01-15

Similar Documents

Publication Publication Date Title
KR102496162B1 (ko) 트랜스티레틴(ttr) 아밀로이드증의 항체-기반의 치료 및 이를 위한 인간-유래의 항체
JP6097690B2 (ja) 抗ｃｘｃｌ１３抗体およびそれを用いる方法
RU2623122C2 (ru) Моноклональные антитела и способы их применения
US6416958B2 (en) Selective apoptosis of neoplastic cells by an HLA-DR specific monoclonal antibody
TWI529247B (zh) 抗人類ｃｄ５２免疫球蛋白
RU2668170C2 (ru) Анти-в7-н3-антитело
JP2021511818A (ja) Ｖｉｓｔａ抗原結合性分子
EA037397B1 (ru) Гуманизированные антитела к рецептору ccr7
JP2017123851A (ja) 結腸癌および膵臓癌に対する組み換えモノクローナル抗体および対応抗原
AU2014312310A1 (en) Novel SEZ6 modulators and methods of use
US20220380472A1 (en) Mage-a4 peptide-mhc antigen binding proteins
US9605079B2 (en) Proteins that bind PI16 and uses thereof
US12435444B2 (en) Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same
US8354507B2 (en) HLA-DR specific antibodies, compositions and methods
TW202110891A (zh) 抗psgl-1組合物及其用於調節骨髓細胞發炎表型之方法及用途
KR20210096612A (ko) IgA 항체 구축물을 포함하는 조성물 및 방법
JP2005502610A (ja) フィブリンのｄ二量体断片に特異的なｄｄ−３ｂ６／２２から誘導されるヒト化抗体
JP2024516769A (ja) 治療用結合分子
US20220275077A1 (en) Il-38-specific antibodies
CN109661406A (zh) 靶向肿瘤相关巨噬细胞的抗体及其用途
WO2022179483A1 (zh) Siglec-15结合蛋白的制备及其用途
HK40116844A (en) Anti-transthyretin antibody, composition thereof, kit, method and use
TW202302635A (zh) Ｉｌ－３８專一性抗體
CN117677396A (zh) Il-38特异性抗体
JPWO2014142356A1 (ja) 強皮症治療剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071109

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071109

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100917

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101215

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101222

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110114

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110121

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110216

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110317

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110520